- Home
- BCAB vs ELTX Comparison
BCAB vs ELTX Comparison
Compare BCAB & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAB
- ELTX
- Stock Information
- Founded
- BCAB 2007
- ELTX 2011
- Country
- BCAB United States
- ELTX United States
- Employees
- BCAB N/A
- ELTX N/A
- Industry
- BCAB Medicinal Chemicals and Botanical Products
- ELTX Biotechnology: Pharmaceutical Preparations
- Sector
- BCAB Health Care
- ELTX Health Care
- Exchange
- BCAB Nasdaq
- ELTX Nasdaq
- Market Cap
- BCAB 96.2M
- ELTX 49.7M
- IPO Year
- BCAB 2020
- ELTX 2021
- Fundamental
- Price
- BCAB $2.08
- ELTX $4.16
- Analyst Decision
- BCAB Strong Buy
- ELTX Buy
- Analyst Count
- BCAB 2
- ELTX 2
- Target Price
- BCAB $6.00
- ELTX $10.00
- AVG Volume (30 Days)
- BCAB 1.6M
- ELTX 16.1K
- Earning Date
- BCAB 11-08-2024
- ELTX 11-07-2024
- Dividend Yield
- BCAB N/A
- ELTX N/A
- EPS Growth
- BCAB N/A
- ELTX N/A
- EPS
- BCAB N/A
- ELTX N/A
- Revenue
- BCAB N/A
- ELTX N/A
- Revenue This Year
- BCAB N/A
- ELTX N/A
- Revenue Next Year
- BCAB N/A
- ELTX N/A
- P/E Ratio
- BCAB N/A
- ELTX N/A
- Revenue Growth
- BCAB N/A
- ELTX N/A
- 52 Week Low
- BCAB $1.14
- ELTX $2.96
- 52 Week High
- BCAB $4.02
- ELTX $11.45
- Technical
- Relative Strength Index (RSI)
- BCAB 55.80
- ELTX 40.82
- Support Level
- BCAB $1.87
- ELTX $4.05
- Resistance Level
- BCAB $2.13
- ELTX $4.89
- Average True Range (ATR)
- BCAB 0.12
- ELTX 0.28
- MACD
- BCAB 0.00
- ELTX -0.06
- Stochastic Oscillator
- BCAB 68.90
- ELTX 27.37
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.